Protectin D1-d5
(Synonyms: Neuroprotectin D1-d5, NPD1-d5, PD1-d5) 目录号 : GC48993An internal standard for the quantification of protectin D1
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Protectin D1-d5 is intended for use as an internal standard for the quantification of protectin D1 by GC- or LC-MS. Protectin D1 is a specialized pro-resolving mediator (SPM) synthesized from docosahexaenoic acid .1 DHA is oxidized to 16S,17S-epoxy protectin, which is converted to protectin D1 enzymatically. Protectin D1 increases phagocytosis of apoptotic polymorphonuclear leukocytes (PMNs) by macrophages in a non-phlogistic manner and is generated in vitro during macrophage-apoptotic interactions.2 It enhances phagocytosis in mice after 24 hours, but not at the initiation or peak of inflammation. It also decreases PMN infiltration in a zymosan-induced mouse model of inflammation when administered at a dose of 300 ng per animal. Protectin D1 (200 µg, i.v.) inhibits increases in neutrophil counts in bronchoalveolar fluid (BALF) and lung myeloperoxidase activity in a mouse model of pulmonary injury and inflammation induced by intratracheal LPS instillation.3 It also decreases pulmonary edema and promotes neutrophil apoptosis in BALF.
1.Rodriguez, A.R., and Spur, B.W.Total synthesis of pro-resolving and tissue-regenerative protectin sulfido-conjugatesTetrahedron Lett.56(42)5811-5815(2015) 2.Schwab, J.M., Chiang, N., Arita, M., et al.Resolvin E1 and protectin D1 activate inflammation-resolution programmesNature447(7146)869-874(2007) 3.Li, X., Li, C., Liang, W., et al.Protectin D1 promotes resolution of inflammation in a murine model of lipopolysaccharide-induced acute lung injury via enhancing neutrophil apoptosisChin. Med. J. (Engl.)127(5)810-814(2014)
Cas No. | N/A | SDF | |
别名 | Neuroprotectin D1-d5, NPD1-d5, PD1-d5 | ||
Canonical SMILES | O[C@@H](C/C=C\C([2H])([2H])C([2H])([2H])[2H])/C=C\C=C\C=C\[C@H](O)C/C=C\C/C=C\CCC(O)=O | ||
分子式 | C22H27D5O4 | 分子量 | 365.5 |
溶解度 | Ethanol: 1 mg/ml | 储存条件 | -80°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.736 mL | 13.6799 mL | 27.3598 mL |
5 mM | 0.5472 mL | 2.736 mL | 5.472 mL |
10 mM | 0.2736 mL | 1.368 mL | 2.736 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。